https://orcid.org/0000-0001-9541-7201
Figures & data
Figure 1. Examples of nucleoside analogue drugs.
Scheme 1. Enzymatic synthesis of α-d-pentose 1-phosphates using a thermostable pyrimidine nucleoside phosphorylase; isolation as Ba2+ salt form facilitates purification by precipitation and gram-scale access; TNP = thymidine nucleoside phosphorylase.
Scheme 2. Diversification of 4’-Me substituted nucleosides using the nucleoside phosphorylase TtDyNP; transglycosylation under thermodynamic reaction control enables the insertion of pyrimidines or purines; R = Me, F, Br, I, CF3; R1 = NH2 or OH; R2 = NH2, H or Cl.
Scheme 3. A) Nucleoside salvage pathway enzymes for the degradation of inosine. B) An engineered pathway for didanosine production. C) Biocatalytic synthesis of islatravir. Engineered enzymes are shown in blue, accessory enzymes in red. RK = ribokinase, PPM = phosphopentomutase, PNP = purine nucleoside phosphorylase, PanK = pantothenate kinase, DERA = deoxyribose 5-phosphate aldolase, PK = pyruvate kinase, AK = adenylate kinase, GOase = galactose oxidase, HRP = horseradish peroxidase.
Scheme 4. Chemoenzymatic synthesis of molnupiravir 12. MTRk = 5-S-methylthirbose kinase, UP = uridine phosphorylase, AcK = acetate kinase, PO = pyruvate oxidase, ATP = adenosine triphosphate.
